Back to results
US 2021/0268076 A1Published application
Treatment of Diseases Related to Hyperactivity of the Complement System
AssigneeCambridge Enterprise Limited
InventorPeter Lachmann
Life of this patent
Estimating the term…
Abstract
Raising the level of Factor I above physiological levels can be used to treat diseases in which the underlying pathology is linked to overactivity of the C3b-feedback cycle and the generation and pro-inflammatory effects of iC3b. Methods, agents, and compositions for treatment of such diseases are described.
Claims9
1-53. (canceled)
A method for treating Age-related Macular Degeneration (AMD) or atypical Hemolytic Uremic Syndrome (aHUS) in a human subject, the method comprising:
- administering a pharmaceutical composition comprising a therapeutically effective amount of an agent providing native Factor I, or a polypeptide that has at least 90% amino acid identity with native Factor I and that retains C3b-inactivating activity and iC3b degrading activity, to the human subject;
- thereby treating AMD or aHUS in the human subject.
A method for treating Age-related Macular Degeneration (AMD) or atypical Hemolytic Uremic Syndrome (aHUS) in a human subject, the method comprising:
- administering a pharmaceutical composition comprising a therapeutically effective amount of an agent selected from native Factor I and a polypeptide that has at least 90% amino acid identity with native Factor I and that retains C3b-inactivating activity and iC3b degrading activity to the human subject;
- thereby treating AMD or aHUS in the human subject.
Dependencies are inferred from the claim text.